Zacks Investment Research cut shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) from a hold rating to a sell rating in a research note released on Wednesday.
According to Zacks, “Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). “
Several other analysts also recently weighed in on the stock. ValuEngine downgraded shares of REDHILL BIOPHAR/S from a hold rating to a sell rating in a research report on Thursday, October 11th. HC Wainwright set a $36.00 price objective on shares of REDHILL BIOPHAR/S and gave the stock a buy rating in a research report on Wednesday, November 14th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. REDHILL BIOPHAR/S presently has an average rating of Hold and a consensus price target of $20.81.
REDHILL BIOPHAR/S (NASDAQ:RDHL) last issued its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.40). REDHILL BIOPHAR/S had a negative net margin of 461.55% and a negative return on equity of 112.99%. The company had revenue of $2.21 million during the quarter, compared to the consensus estimate of $2.54 million. On average, equities analysts expect that REDHILL BIOPHAR/S will post -1.76 EPS for the current fiscal year.
Several large investors have recently modified their holdings of RDHL. Disciplined Growth Investors Inc. MN purchased a new stake in shares of REDHILL BIOPHAR/S during the 3rd quarter worth approximately $295,000. Clear Harbor Asset Management LLC purchased a new stake in shares of REDHILL BIOPHAR/S during the 3rd quarter worth approximately $323,000. JPMorgan Chase & Co. lifted its position in shares of REDHILL BIOPHAR/S by 61.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 73,878 shares of the biotechnology company’s stock worth $652,000 after buying an additional 28,102 shares during the last quarter. ARK Investment Management LLC lifted its position in shares of REDHILL BIOPHAR/S by 8.6% during the 2nd quarter. ARK Investment Management LLC now owns 112,648 shares of the biotechnology company’s stock worth $961,000 after buying an additional 8,894 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of REDHILL BIOPHAR/S during the 3rd quarter worth approximately $1,226,000. Institutional investors and hedge funds own 32.27% of the company’s stock.
REDHILL BIOPHAR/S Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.
Featured Story: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.